Do analysts rate BON or ADXS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Ayala Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, BON or ADXS?

Bon Natural Life has higher revenue and earnings than Ayala Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bon Natural Life $18.67M 0.51 -$2M N/A N/A Ayala Pharmaceuticals $3.24M 11.05 -$48.07M -$5.02 N/A

Is BON or ADXS more profitable?

Company Net Margins Return on Equity Return on Assets Bon Natural Life N/A N/A N/A Ayala Pharmaceuticals N/A N/A N/A

Do analysts recommend GRML or BON?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, GRML or BON?

Bon Natural Life has higher revenue and earnings than Greenland Mines Ltd. Common Stock. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Greenland Mines Ltd. Common Stock N/A N/A -$10.55M -$0.32 N/A Bon Natural Life $18.67M 0.51 -$2M N/A N/A

Is GRML or BON more profitable?

Bon Natural Life's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Greenland Mines Ltd. Common Stock N/A -109.40% -98.80% Bon Natural Life N/A N/A N/A

Do analysts prefer BON or ALGS?

Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 588.73%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Bon Natural Life. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Which has higher valuation & earnings, BON or ALGS?

Bon Natural Life has higher revenue and earnings than Aligos Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bon Natural Life $18.67M 0.51 -$2M N/A N/A Aligos Therapeutics $2.19M 15.80 -$24.19M -$8.69 N/A

Do analysts rate SNTI or BON?

Senti Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 834.58%. Given Senti Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Senti Biosciences is more favorable than Bon Natural Life. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Senti Biosciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, SNTI or BON?

Bon Natural Life has higher revenue and earnings than Senti Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Senti Biosciences $20K 1,666.53 -$61.44M -$1.92 N/A Bon Natural Life $18.67M 0.51 -$2M N/A N/A

Is SNTI or BON more profitable?

Bon Natural Life's return on equity of 0.00% beat Senti Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Senti Biosciences N/A -532.05% -103.35% Bon Natural Life N/A N/A N/A

Do analysts recommend ZYBT or BON?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, ZYBT or BON?

Bon Natural Life has higher revenue and earnings than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Zhengye Biotechnology $16.64M 1.84 -$9.98M N/A N/A Bon Natural Life $18.67M 0.51 -$2M N/A N/A

Is ZYBT or BON more profitable?

Company Net Margins Return on Equity Return on Assets Zhengye Biotechnology N/A N/A N/A Bon Natural Life N/A N/A N/A

Bon Natural Life (BON) Competitors

$1.18 0.00 (0.00%)

Closing price 07/2/2026 03:51 PM Eastern

Extended Trading

$1.19 +0.01 (+0.85%)

As of 07/2/2026 07:55 PM Eastern

Compare

BON vs. ADXS, GRML, ALGS, SNTI, and ZYBT

Should you buy Bon Natural Life stock or one of its competitors? MarketBeat compares Bon Natural Life with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bon Natural Life include Ayala Pharmaceuticals (ADXS), Greenland Mines Ltd. Common Stock (GRML), Aligos Therapeutics (ALGS), Senti Biosciences (SNTI), and Zhengye Biotechnology (ZYBT). These companies are all part of the "pharmaceutical products" industry.

How does Bon Natural Life compare to Ayala Pharmaceuticals?

Bon Natural Life (NASDAQ:BON) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

Bon Natural Life has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

Bon Natural Life has higher revenue and earnings than Ayala Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bon Natural Life	$18.67M	0.51	-$2M	N/A	N/A
Ayala Pharmaceuticals	$3.24M	11.05	-$48.07M	-$5.02	N/A

0.6% of Bon Natural Life shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Bon Natural Life	N/A	N/A	N/A
Ayala Pharmaceuticals	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Ayala Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Ayala Pharmaceuticals had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for Ayala Pharmaceuticals and 0 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 0.00 equaled Ayala Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Bon Natural Life	Neutral
Ayala Pharmaceuticals	Neutral

Summary

Bon Natural Life and Ayala Pharmaceuticals tied by winning 4 of the 8 factors compared between the two stocks.

How does Bon Natural Life compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, earnings, risk, profitability, institutional ownership, dividends and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Greenland Mines Ltd. Common Stock has a beta of 7.05, indicating that its stock price is 605% more volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market.

Bon Natural Life has higher revenue and earnings than Greenland Mines Ltd. Common Stock.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A
Bon Natural Life	$18.67M	0.51	-$2M	N/A	N/A

Bon Natural Life's return on equity of 0.00% beat Greenland Mines Ltd. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%
Bon Natural Life	N/A	N/A	N/A

20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are owned by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are owned by insiders. Comparatively, 26.5% of Bon Natural Life shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Greenland Mines Ltd. Common Stock had 2 more articles in the media than Bon Natural Life. MarketBeat recorded 2 mentions for Greenland Mines Ltd. Common Stock and 0 mentions for Bon Natural Life. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.30 beat Bon Natural Life's score of 0.00 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the media.

Company	Overall Sentiment
Greenland Mines Ltd. Common Stock	Neutral
Bon Natural Life	Neutral

Summary

Bon Natural Life beats Greenland Mines Ltd. Common Stock on 5 of the 9 factors compared between the two stocks.

How does Bon Natural Life compare to Aligos Therapeutics?

Bon Natural Life (NASDAQ:BON) and Aligos Therapeutics (NASDAQ:ALGS) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, media sentiment, dividends, valuation, analyst recommendations and profitability.

Bon Natural Life has higher revenue and earnings than Aligos Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bon Natural Life	$18.67M	0.51	-$2M	N/A	N/A
Aligos Therapeutics	$2.19M	15.80	-$24.19M	-$8.69	N/A

Bon Natural Life has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market. Comparatively, Aligos Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the broader market.

Bon Natural Life has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Bon Natural Life's return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bon Natural Life	N/A	N/A	N/A
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%

In the previous week, Aligos Therapeutics had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for Aligos Therapeutics and 0 mentions for Bon Natural Life. Bon Natural Life's average media sentiment score of 0.00 equaled Aligos Therapeutics'average media sentiment score.

Company	Overall Sentiment
Bon Natural Life	Neutral
Aligos Therapeutics	Neutral

Aligos Therapeutics has a consensus target price of $38.50, suggesting a potential upside of 588.73%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Aligos Therapeutics is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

0.6% of Bon Natural Life shares are held by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are held by institutional investors. 26.5% of Bon Natural Life shares are held by insiders. Comparatively, 7.8% of Aligos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Aligos Therapeutics beats Bon Natural Life on 8 of the 14 factors compared between the two stocks.

How does Bon Natural Life compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk and earnings.

Bon Natural Life's return on equity of 0.00% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Bon Natural Life	N/A	N/A	N/A

In the previous week, Senti Biosciences had 1 more articles in the media than Bon Natural Life. MarketBeat recorded 1 mentions for Senti Biosciences and 0 mentions for Bon Natural Life. Senti Biosciences' average media sentiment score of 0.67 beat Bon Natural Life's score of 0.00 indicating that Senti Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Senti Biosciences	Positive
Bon Natural Life	Neutral

25.7% of Senti Biosciences shares are held by institutional investors. Comparatively, 0.6% of Bon Natural Life shares are held by institutional investors. 3.1% of Senti Biosciences shares are held by company insiders. Comparatively, 26.5% of Bon Natural Life shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Senti Biosciences has a beta of 2.04, suggesting that its stock price is 104% more volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, suggesting that its stock price is 117% less volatile than the broader market.

Senti Biosciences currently has a consensus target price of $10.00, suggesting a potential upside of 834.58%. Given Senti Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Senti Biosciences is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bon Natural Life has higher revenue and earnings than Senti Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,666.53	-$61.44M	-$1.92	N/A
Bon Natural Life	$18.67M	0.51	-$2M	N/A	N/A

Summary

Senti Biosciences beats Bon Natural Life on 9 of the 14 factors compared between the two stocks.

How does Bon Natural Life compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Bon Natural Life (NASDAQ:BON) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

In the previous week, Zhengye Biotechnology's average media sentiment score of 0.00 equaled Bon Natural Life'saverage media sentiment score.

Company	Overall Sentiment
Zhengye Biotechnology	Neutral
Bon Natural Life	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
Zhengye Biotechnology	N/A	N/A	N/A
Bon Natural Life	N/A	N/A	N/A

0.6% of Bon Natural Life shares are owned by institutional investors. 26.5% of Bon Natural Life shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Zhengye Biotechnology has a beta of -2.18, indicating that its share price is 318% less volatile than the broader market. Comparatively, Bon Natural Life has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market.

Bon Natural Life has higher revenue and earnings than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zhengye Biotechnology	$16.64M	1.84	-$9.98M	N/A	N/A
Bon Natural Life	$18.67M	0.51	-$2M	N/A	N/A

Summary

Bon Natural Life beats Zhengye Biotechnology on 5 of the 6 factors compared between the two stocks.

Get Bon Natural Life News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BON vs. The Competition

Export

Metric	Bon Natural Life	CONSM PD Industry	Discretionary Sector	NASDAQ Exchange
Market Cap	$9.58M	$1.52B	$7.36B	$12.48B
Dividend Yield	N/A	4.84%	3.03%	6.52%
P/E Ratio	N/A	9.11	20.70	24.70
Price / Sales	0.51	3.28	4.20	99.42
Price / Cash	N/A	16.92	15.55	57.09
Price / Book	0.17	1.46	3.84	6.46
Net Income	-$2M	$61.01M	$247.92M	$337.01M
7 Day Performance	4.34%	1.18%	0.46%	1.69%
1 Month Performance	-5.68%	9.07%	2.55%	3.81%
1 Year Performance	-21.40%	0.25%	0.53%	23.90%

Bon Natural Life Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BON Bon Natural Life	0.8697 of 5 stars	$1.18 flat	N/A	-21.4%	$9.58M	$18.67M	N/A	100	Gap Down
ADXS Ayala Pharmaceuticals	N/A	$0.60 flat	N/A	N/A	$35.79M	$3.24M	N/A	20
GRML Greenland Mines Ltd. Common Stock	0.6351 of 5 stars	$0.26 flat	N/A	-79.6%	$35.35M	N/A	N/A	5	Gap Up
ALGS Aligos Therapeutics	2.3362 of 5 stars	$5.57 flat	$38.50 +591.2%	-29.7%	$34.48M	$2.19M	N/A	90	News Coverage
SNTI Senti Biosciences	2.6938 of 5 stars	$1.09 flat	$10.00 +817.4%	-52.8%	$33.95M	$20K	N/A	4	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BON) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bon Natural Life (BON) Competitors

BON vs. ADXS, GRML, ALGS, SNTI, and ZYBT

How does Bon Natural Life compare to Ayala Pharmaceuticals?

Summary

How does Bon Natural Life compare to Greenland Mines Ltd. Common Stock?

Summary

How does Bon Natural Life compare to Aligos Therapeutics?

Summary

How does Bon Natural Life compare to Senti Biosciences?

Summary

How does Bon Natural Life compare to Zhengye Biotechnology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BON vs. The Competition

Bon Natural Life Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bon Natural Life (BON) Competitors

BON vs. ADXS, GRML, ALGS, SNTI, and ZYBT

How does Bon Natural Life compare to Ayala Pharmaceuticals?

Which has more risk & volatility, BON or ADXS?

Which has better valuation & earnings, BON or ADXS?

Do institutionals & insiders hold more shares of BON or ADXS?

Is BON or ADXS more profitable?

Do analysts rate BON or ADXS?

Does the media refer more to BON or ADXS?

Summary

How does Bon Natural Life compare to Greenland Mines Ltd. Common Stock?

Do analysts recommend GRML or BON?

Which has more volatility and risk, GRML or BON?

Which has stronger earnings and valuation, GRML or BON?

Is GRML or BON more profitable?

Do insiders & institutionals believe in GRML or BON?

Does the media favor GRML or BON?

Summary

How does Bon Natural Life compare to Aligos Therapeutics?

Which has higher valuation & earnings, BON or ALGS?

Which has more volatility & risk, BON or ALGS?

Is BON or ALGS more profitable?

Does the media favor BON or ALGS?

Do analysts prefer BON or ALGS?

Do insiders and institutionals have more ownership in BON or ALGS?

Summary

How does Bon Natural Life compare to Senti Biosciences?

Is SNTI or BON more profitable?

Does the media favor SNTI or BON?

Do insiders & institutionals have more ownership in SNTI or BON?

Which has more risk & volatility, SNTI or BON?

Do analysts rate SNTI or BON?

Which has higher earnings & valuation, SNTI or BON?

Summary

How does Bon Natural Life compare to Zhengye Biotechnology?

Does the media prefer ZYBT or BON?

Do analysts recommend ZYBT or BON?

Is ZYBT or BON more profitable?

Do institutionals and insiders believe in ZYBT or BON?

Which has more volatility & risk, ZYBT or BON?

Which has stronger valuation and earnings, ZYBT or BON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BON vs. The Competition

Bon Natural Life Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools